September 4, 2019

The draft specialty drug list for 2019 Q2 is now available for public comment.

A drug must meet all four of the rule criteria to be considered for inclusion on the HHSC specialty drug list (SDL). HHSC publishes a draft version of the SDL each quarter and welcomes stakeholder input on the drugs included on the draft.

Comment on the draft SDL is accepted until Thursday, Sept. 19. Comments should be submitted on the Specialty Drug Submission Spreadsheet (XLS). The Specialty Drug List Process (PDF) outlines the process for including drugs on the SDL and expectations for external comment:

  • Requests for additions to the SDL must include documentation justifying the drug meets three of the four of the rule criteria
  • Requests for removals from the SDL must include documentation justifying the drug does not meet at least one of the rule criteria
  • The form allows justification of criteria #1, #3, and #4. Criteria #2 will be verified by HHSC through review of drug utilization data

Drugs marked as "approved" are scheduled for inclusion on the final SDL scheduled for publication in June. Questions or comments about the SDL processes should be sent by email to